Axogen, Inc.

    Axogen, Inc.

    BBIVA:AXGN
    - -
    MXN
    - -
    - -
    -11.67EPS
    2013 Y
    2014 Y
    2015 Y
    2016 Y
    2017 Y
    2018 Y
    2019 Y
    2020 Y
    2021 Y
    2022 Y
    2023 Y
    2024 Y
    2025 Y
    TTM
    Revenue per Share
    0.81
    0.95
    1.05
    1.34
    1.81
    2.26
    2.72
    2.81
    3.09
    3.29
    3.71
    4.23
    4.89
    5.07
    Basic EPS, GAAP
    -1.08
    -1
    -0.51
    -0.47
    -0.31
    -0.6
    -0.74
    -0.6
    -0.65
    -0.69
    -0.51
    -0.23
    -0.34
    -0.68
    Free Cash Flow per Basic Share
    -0.79
    -0.62
    -0.52
    -0.4
    -0.32
    -0.66
    -0.64
    -0.81
    -1.01
    -0.89
    -0.48
    - -
    -0.1
    0.13
    Dividend per Share
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Book Value per Share
    0.01
    -0.58
    0.27
    0.45
    0.73
    3.78
    3.34
    3.03
    2.7
    2.38
    2.22
    2.35
    2.73
    4.82
    Tangible Book Value per Share
    -0.03
    -0.61
    0.25
    0.43
    0.71
    3.75
    3.3
    2.98
    2.63
    2.29
    2.11
    2.23
    2.59
    4.68
    Basic Weighted Avg Shares
    13
    18
    26
    31
    33
    37
    39
    40
    41
    42
    43
    44
    46
    50
    Sales/Revenue/Turnover
    11
    17
    27
    41
    60
    84
    107
    112
    127
    139
    159
    187
    225
    251
    Operating Margin (%)
    -87.62
    -58.28
    -33.91
    -19.78
    -13.16
    -24.42
    -29.43
    -20.64
    -19.96
    -21.44
    -13.5
    -1.75
    -3.49
    -5.12
    Depreciation Expense
    - -
    - -
    - -
    - -
    1
    1
    3
    3
    5
    5
    6
    8
    9
    9
    Net Income, GAAP
    -15
    -18
    -13
    -14
    -10
    -22
    -29
    -24
    -27
    -29
    -22
    -10
    -16
    -34
    Effective Tax Rate (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Profit Margin (%)
    -132.97
    -105.31
    -48.87
    -35.06
    -17.29
    -26.68
    -27.3
    -21.18
    -21.19
    -20.89
    -13.66
    -5.32
    -6.97
    -13.36
    Working Capital
    24
    12
    31
    33
    42
    138
    114
    122
    103
    74
    58
    69
    97
    170
    LT Debt
    25
    25
    25
    20
    20
    - -
    2
    53
    66
    66
    68
    67
    65
    18
    Total Equity
    - -
    -11
    8
    15
    25
    147
    132
    123
    113
    101
    96
    104
    129
    256
    Return on Invested Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Capital (%)
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    - -
    Return on Common Equity (%)
    - -
    - -
    - -
    -124.68
    -52.09
    -26.02
    -20.88
    -18.63
    -22.9
    -27.11
    -22.08
    -9.99
    -13.49
    -18.21

    Capital Structure

    USD

    •

    in mil. unless spec.
    Dec'25
    Mar'26
    Jun'26
    ST Debt
    2
    2
    2
    LT Borrowings
    48
    - -
    - -
    LT Finance Leases
    17
    19
    18
    Preferred Equity and Hybrid Capital
    - -
    - -
    - -
    Shares Outstanding
    47
    53
    53
    Market Capitalization
    - -
    - -
    - -

    Working Capital

    USD

    •

    in mil. unless spec.
    Dec'25
    Mar'26
    Jun'26
    Total Current Assets
    120
    185
    200
    Cash, Cash Equivalents & STI
    42
    102
    111
    Accounts Receivable, Net
    26
    28
    34
    Inventories
    42
    46
    47
    Total Current Liabilities
    24
    26
    30
    Payables & Accruals
    5
    24
    28
    ST Debt
    2
    2
    2
    Deferred Revenue
    - -
    - -
    - -

    Growth Rates

    USD

    •

    in mil. unless spec.

    (avg. rate of change)

    10 years
    5 years
    1 year
    Total Equity
    62.61%
    1.69%
    24%
    Free Cash Flow
    -4,355.91%
    -8,739.7%
    -43,572.73%
    Net Income, GAAP
    10.57%
    -0.16%
    57.6%
    Sales/Revenue/Turnover
    24.37%
    15%
    20.21%
    Total Cash Common Dividend
    - -
    - -
    - -

    Quarterly Revenue

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2024
    41
    48
    49
    49
    187
    2025
    49
    57
    60
    60
    225
    2026
    61
    70
    - -
    - -
    - -

    Quarterly Earnings Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2024
    -0.15
    -0.04
    -0.04
    0.01
    -0.23
    2025
    -0.08
    0.01
    0.02
    -0.28
    -0.34
    2026
    -0.38
    -0.03
    - -
    - -
    - -

    Quarterly Dividends Per Share

    USD

    •

    in mil. unless spec.

    Year

    Q1
    Q2
    Q3
    Q4
    FY
    2024
    - -
    - -
    - -
    - -
    - -
    2025
    - -
    - -
    - -
    - -
    - -
    2026
    - -
    - -
    - -
    - -
    - -

    Company Description

    Company Profile APIChatGPT
    Address
    Similar Companies
    Business
    Axogen, Inc. is a medical technology company that develops and commercializes surgical solutions for peripheral nerve regeneration and repair. The company offers a comprehensive portfolio of regenerative medicine products designed to restore nerve function and sensation for patients with peripheral nerve injuries, including Avance Nerve Graft, a decellularized and biologically active processed human nerve allograft used to bridge peripheral nerve gaps without autograft-related donor site morbidity; Axoguard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid designed for tensionless connection and alignment of severed nerve ends; Axoguard Nerve Protector, a porcine submucosa extracellular matrix wrap engineered to shield injured or compressed nerves and minimize soft tissue attachments; Axoguard Nerve Cap, an extracellular matrix implant engineered to cover transected nerve ends to prevent symptomatic neuroma formation; Avive+ Soft Tissue Matrix, a multi-layered resorbable human umbilical cord tissue barrier designed to protect healing tissues and reduce inflammation; and Axotouch Two-Point Discriminator, a sensory measurement device used to evaluate and monitor cutaneous sensory innervation recovery. Axogen markets its surgical solutions to hospitals, ambulatory surgery centers, and surgical specialists, including orthopedic hand surgeons, plastic and reconstructive surgeons, oral and maxillofacial surgeons, and trauma surgeons. Founded in 2002 and headquartered in Alachua, Florida, the company conducts its primary commercial operations in the United States and distributes its products internationally through direct sales channels and independent distributor networks. In recent developments, Axogen completed the submission of its Biologics License Application to the U.S. Food and Drug Administration for Avance Nerve Graft, supported by clinical data from its pivotal RECON study, facilitating a strategic transition from a human cellular and tissue-based product to a licensed biological product. The company also fully operationalized its state-of-the-art biological processing center and distribution facility in Alachua, Florida, significantly expanding in-house manufacturing capacity and supply chain resilience. Additionally, Axogen expanded its commercial focus across surgical chronic pain management and sensory restoration in post-mastectomy breast reconstruction through its Resensation initiative, introduced line extensions within its soft tissue matrix portfolio, and restructured its debt facilities to strengthen long-term liquidity and support commercial growth.